<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356590</url>
  </required_header>
  <id_info>
    <org_study_id>20021623</org_study_id>
    <secondary_id>16.0023</secondary_id>
    <nct_id>NCT00356590</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012</brief_title>
  <official_title>Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is an open label, multicenter study for extended treatment of patients who have
      participated in the Immunex clinical study 016.0012. The primary objective of this study is
      to evaluate the long term safety of etanercept (TNFR:Fc) in patients with early stage
      rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1998</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Exposure to Etanercept With Gaps</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Total participant exposure to etanercept (Enbrel) with gaps, calculated as the sum of the times on treatment for all participants. Gaps of up to 14 days from the last treatment in a previous Etanercept study were ignored in calculating time on treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Exposure-Adjusted Rate of Malignancies</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Exposure-adjusted rate of malignancies, excluding nonmelanoma skin cancers, occurring on study within 30 days of the last dose of etanercept</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Exposure-Adjusted Rate of Deaths</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Rate of deaths within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Exposure Adjusted Rate of Serious Infectious Events</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Exposure-adjusted rate of serious infectious events (associated with hospitalization or IV antibiotics) occurring on study within 30 days of the last dose of etanercept</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Exposure Adjusted Rate of Lymphomas</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Rate of lymphomas occurring on study within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malignancy</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Occurrence of one or more malignancies within the participant on study within 30 days of the last dose of etanercept</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphoma</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Occurrence of one or more lymphomas on study within 30 days of the last dose of etanercept</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Infectious Event</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Occurrence of one or more serious infectious events within the participant on study within 30 days of the last dose of study medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Exposure Adjusted Rate of Serious Adverse Events</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Rate of serious adverse events adjusted to total exposure to etanercept (events / exposure * 100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Death of the participant on study up to 30 days after the last dose of etanercept</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20 Response at Month 3</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (physician and patient global assessments, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein or erythrocyte sedimentation rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing Period</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Duration of etanercept dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR20 Response at Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR50 Response at Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>American College of Rheumatology (ACR) 50, defined as a 50% improvement in both tender and swollen joints (78 joints) and a 50% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR70 Response at Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>American College of Rheumatology (ACR) 70, defined as a 70% improvement in both tender and swollen joints (78 joints) and a 70% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Incidence Rate for All SEER Cancers</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Standardized incidence rate for all cancers tracked by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) system, calculated as the ratio of the observed to expected age- and sex-adjusted incidence rates (per person-year) of cancer. Expected rates were based on 1998-2002 SEER data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Physician Global Assessment of Disease Status From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in the Physician Global Assessment of disease status from baseline to month 12, assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Participant Global Assessment of Disease Status From Baseline to Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Percent improvement in the Participant Global Assessment of disease status from baseline to month 12, assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Participant Pain Visual Analog Scale From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in the Participant Pain Visual Analog Scale (VAS) from baseline to month 12, using a 10 cm scale ranging from &quot;no pain&quot; (0 cm) to &quot;severe pain&quot; (10 cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Tender Joint Count From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in tender joint count (based on up to 71 joints) from baseline to month 12. Tender joints were assessed clinically, and the number of such joints was counted at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Swollen Joint Count From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in swollen joint count (based on up to 68 joints) from baseline to month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in HAQ DI From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in the Health Assessment Questionnaire Disability Index (HAQ DI) from baseline to month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in the Physical Component Summary Score for SF-36 From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in the Physical Component Summary Score for the Short Form 36 Health Survey (SF-36) from baseline to month 12. This score has a range of 0 to 100, with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Mental Component Summary Score of SF-36 From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in the Mental Component Summary Score of the Short Form 36 Health Survey (SF-36) from baseline to month 12. This score has a range of 0 to 100, with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in C-Reactive Protein From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in C-reactive protein from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in Duration of Morning Stiffness From Baseline to Month 12</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent improvement in the duration of morning stiffness from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Year 2 in Total Sharp Score</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>Change from baseline to year 2 in Total Sharp Score. This score has a range of 0 to 398, where 0 = no change and higher scores represent a worsening of joint erosions and joint space narrowing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Year 2 in Sharp Score Erosion Subscale</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>Change from baseline to year 2 in the joint erosion subscale of the Total Sharp Score. This subscale has a range of 0 to 230, where 0 = no change and higher values represent a worsening in joint erosions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Year 2 in Sharp Score Joint Space Narrowing Subscale</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>Change from baseline to year 2 in the joint space narrowing subscale of the Total Sharp Score. This subscale has a range of 0 to 168, where 0 = no change and higher values represent a worsening of joint space narrowing.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Previous enrollment in Immunex protocol 016.0012.

          -  No clinically significant adverse events thought to be due to etanercept (TNFR:Fc)
             during previous treatment.

          -  Negative serum pregnancy test not more than 14 days before the first dose of study
             drug in females of childbearing potential.

          -  No more than one NSAID at a dose not greater than the maximum recommended dose and
             stable for at least two weeks prior to administration of etanercept (TNFR:Fc).
             Exclusion Criteria:

          -  Previous receipt of etanercept (TNFR:Fc) (p55), antibody to TNF, anti-CD4 antibody, or
             diphtheria IL-2 fusion protein.

          -  Receipt of investigational drugs or biologics (other than etanercept (TNFR:Fc)) within
             interval between study drug in 016.0012 and this study.

          -  Receipt of DMARDs (e.g., hydroxychloroquine, oral or injectable gold, azathioprine,
             cyclosporin, D-penicillamine, sulfasalazine, minocycline, or leflunomide) other than
             MTX within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.

          -  Receipt of cyclophosphamide within 1 month prior to the first dose of etanercept
             (TNFR:Fc) in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, Tsuji WH, Leff JA. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005 Jul;32(7):1232-42.</citation>
    <PMID>15996057</PMID>
  </results_reference>
  <results_reference>
    <citation>Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443-50.</citation>
    <PMID>12115173</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <results_first_submitted>November 5, 2010</results_first_submitted>
  <results_first_submitted_qc>November 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2010</results_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Long-term Safety</keyword>
  <keyword>Enbrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 3 March 1999 through 17 Mar 2000</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept (Enbrel)</title>
          <description>Etanercept 50 mg subcutaneous dose weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed month 12 only</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol issues</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Response status</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept (Enbrel)</title>
          <description>Etanercept 50 mg subcutaneous dose weekly</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.38" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment of Disease Status</title>
          <description>Assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.32" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participant Global Assessment of Disease Status</title>
          <description>Assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.51" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participant Pain Visual Analog Scale</title>
          <description>Assessed using a 10 cm scale ranging from &quot;no pain&quot; (0 cm) to &quot;severe pain&quot; (10 cm).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.01" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>Based on up to 71 joints</description>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.81" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>Based on up to 68 joints</description>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.30" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire Disability Index</title>
          <description>This index is a weighted average of 24 items, each scored 0 (no difficulty) to 3 (unable to function).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.30" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical Component Summary Score from SF-36</title>
          <description>Physical Component Summary Score from the Short Form-36 Health Survey. This score has a range of 0 to 100, with higher scores indicating better health.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.42" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mental Component Summary Score from SF-36</title>
          <description>Mental Component Summary Score from the Short Form-36 Health Survey. This score has a range of 0 to 100, with higher scores indicating better health.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.28" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.28" spread="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Morning Stiffness</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182.24" spread="286.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Exposure to Etanercept With Gaps</title>
        <description>Total participant exposure to etanercept (Enbrel) with gaps, calculated as the sum of the times on treatment for all participants. Gaps of up to 14 days from the last treatment in a previous Etanercept study were ignored in calculating time on treatment.</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure to Etanercept With Gaps</title>
          <description>Total participant exposure to etanercept (Enbrel) with gaps, calculated as the sum of the times on treatment for all participants. Gaps of up to 14 days from the last treatment in a previous Etanercept study were ignored in calculating time on treatment.</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2882.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR20 Response at Month 3</title>
        <description>American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (physician and patient global assessments, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein or erythrocyte sedimentation rate)</description>
        <time_frame>Baseline and month 3</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data at month 3</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response at Month 3</title>
          <description>American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (physician and patient global assessments, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein or erythrocyte sedimentation rate)</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data at month 3</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Exposure-Adjusted Rate of Malignancies</title>
        <description>Exposure-adjusted rate of malignancies, excluding nonmelanoma skin cancers, occurring on study within 30 days of the last dose of etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure-Adjusted Rate of Malignancies</title>
          <description>Exposure-adjusted rate of malignancies, excluding nonmelanoma skin cancers, occurring on study within 30 days of the last dose of etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Malignancies per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Exposure-Adjusted Rate of Deaths</title>
        <description>Rate of deaths within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure-Adjusted Rate of Deaths</title>
          <description>Rate of deaths within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Deaths per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Exposure Adjusted Rate of Serious Infectious Events</title>
        <description>Exposure-adjusted rate of serious infectious events (associated with hospitalization or IV antibiotics) occurring on study within 30 days of the last dose of etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure Adjusted Rate of Serious Infectious Events</title>
          <description>Exposure-adjusted rate of serious infectious events (associated with hospitalization or IV antibiotics) occurring on study within 30 days of the last dose of etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Events per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Exposure Adjusted Rate of Lymphomas</title>
        <description>Rate of lymphomas occurring on study within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure Adjusted Rate of Lymphomas</title>
          <description>Rate of lymphomas occurring on study within 30 days of the last dose of etanercept, adjusted for total exposure to etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Lymphomas per 100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Malignancy</title>
        <description>Occurrence of one or more malignancies within the participant on study within 30 days of the last dose of etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Malignancy</title>
          <description>Occurrence of one or more malignancies within the participant on study within 30 days of the last dose of etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lymphoma</title>
        <description>Occurrence of one or more lymphomas on study within 30 days of the last dose of etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphoma</title>
          <description>Occurrence of one or more lymphomas on study within 30 days of the last dose of etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Infectious Event</title>
        <description>Occurrence of one or more serious infectious events within the participant on study within 30 days of the last dose of study medication</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Infectious Event</title>
          <description>Occurrence of one or more serious infectious events within the participant on study within 30 days of the last dose of study medication</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Exposure Adjusted Rate of Serious Adverse Events</title>
        <description>Rate of serious adverse events adjusted to total exposure to etanercept (events / exposure * 100)</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure Adjusted Rate of Serious Adverse Events</title>
          <description>Rate of serious adverse events adjusted to total exposure to etanercept (events / exposure * 100)</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosing Period</title>
        <description>Duration of etanercept dosing</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Dosing Period</title>
          <description>Duration of etanercept dosing</description>
          <population>All participants who received at least one dose of etanercept</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2249.6" spread="1180.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR20 Response at Month 12</title>
        <description>American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response at Month 12</title>
          <description>American College of Rheumatology (ACR) 20, defined as a 20% improvement in both tender and swollen joints (78 joints) and a 20% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data at month 12</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR50 Response at Month 12</title>
        <description>American College of Rheumatology (ACR) 50, defined as a 50% improvement in both tender and swollen joints (78 joints) and a 50% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response at Month 12</title>
          <description>American College of Rheumatology (ACR) 50, defined as a 50% improvement in both tender and swollen joints (78 joints) and a 50% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data at month 12</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR70 Response at Month 12</title>
        <description>American College of Rheumatology (ACR) 70, defined as a 70% improvement in both tender and swollen joints (78 joints) and a 70% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data at month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>ACR70 Response at Month 12</title>
          <description>American College of Rheumatology (ACR) 70, defined as a 70% improvement in both tender and swollen joints (78 joints) and a 70% improvement in 3 of 5 items (including physician and patient global assessments), in adults</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data at month 12</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Incidence Rate for All SEER Cancers</title>
        <description>Standardized incidence rate for all cancers tracked by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) system, calculated as the ratio of the observed to expected age- and sex-adjusted incidence rates (per person-year) of cancer. Expected rates were based on 1998-2002 SEER data.</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Incidence Rate for All SEER Cancers</title>
          <description>Standardized incidence rate for all cancers tracked by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) system, calculated as the ratio of the observed to expected age- and sex-adjusted incidence rates (per person-year) of cancer. Expected rates were based on 1998-2002 SEER data.</description>
          <population>All participants who received at least one dose of etanercept</population>
          <units>Standardized incidence rate</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.67" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Physician Global Assessment of Disease Status From Baseline to Month 12</title>
        <description>Percent improvement in the Physician Global Assessment of disease status from baseline to month 12, assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Physician Global Assessment of Disease Status From Baseline to Month 12</title>
          <description>Percent improvement in the Physician Global Assessment of disease status from baseline to month 12, assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.07" spread="58.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Participant Global Assessment of Disease Status From Baseline to Month 12</title>
        <description>Percent improvement in the Participant Global Assessment of disease status from baseline to month 12, assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Participant Global Assessment of Disease Status From Baseline to Month 12</title>
          <description>Percent improvement in the Participant Global Assessment of disease status from baseline to month 12, assessed using a 0 - 10 Likert scale, where 0 = asymptomatic and 10 = severe symptoms</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.46" spread="60.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Participant Pain Visual Analog Scale From Baseline to Month 12</title>
        <description>Percent improvement in the Participant Pain Visual Analog Scale (VAS) from baseline to month 12, using a 10 cm scale ranging from &quot;no pain&quot; (0 cm) to &quot;severe pain&quot; (10 cm).</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Participant Pain Visual Analog Scale From Baseline to Month 12</title>
          <description>Percent improvement in the Participant Pain Visual Analog Scale (VAS) from baseline to month 12, using a 10 cm scale ranging from &quot;no pain&quot; (0 cm) to &quot;severe pain&quot; (10 cm).</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.64" spread="103.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Tender Joint Count From Baseline to Month 12</title>
        <description>Percent improvement in tender joint count (based on up to 71 joints) from baseline to month 12. Tender joints were assessed clinically, and the number of such joints was counted at each time point.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Tender Joint Count From Baseline to Month 12</title>
          <description>Percent improvement in tender joint count (based on up to 71 joints) from baseline to month 12. Tender joints were assessed clinically, and the number of such joints was counted at each time point.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.70" spread="147.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Swollen Joint Count From Baseline to Month 12</title>
        <description>Percent improvement in swollen joint count (based on up to 68 joints) from baseline to month 12.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Swollen Joint Count From Baseline to Month 12</title>
          <description>Percent improvement in swollen joint count (based on up to 68 joints) from baseline to month 12.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.04" spread="87.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in HAQ DI From Baseline to Month 12</title>
        <description>Percent improvement in the Health Assessment Questionnaire Disability Index (HAQ DI) from baseline to month 12.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in HAQ DI From Baseline to Month 12</title>
          <description>Percent improvement in the Health Assessment Questionnaire Disability Index (HAQ DI) from baseline to month 12.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="420"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.91" spread="66.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in the Physical Component Summary Score for SF-36 From Baseline to Month 12</title>
        <description>Percent improvement in the Physical Component Summary Score for the Short Form 36 Health Survey (SF-36) from baseline to month 12. This score has a range of 0 to 100, with higher scores indicating better health.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in the Physical Component Summary Score for SF-36 From Baseline to Month 12</title>
          <description>Percent improvement in the Physical Component Summary Score for the Short Form 36 Health Survey (SF-36) from baseline to month 12. This score has a range of 0 to 100, with higher scores indicating better health.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.65" spread="55.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Mental Component Summary Score of SF-36 From Baseline to Month 12</title>
        <description>Percent improvement in the Mental Component Summary Score of the Short Form 36 Health Survey (SF-36) from baseline to month 12. This score has a range of 0 to 100, with higher scores indicating better health.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Mental Component Summary Score of SF-36 From Baseline to Month 12</title>
          <description>Percent improvement in the Mental Component Summary Score of the Short Form 36 Health Survey (SF-36) from baseline to month 12. This score has a range of 0 to 100, with higher scores indicating better health.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.31" spread="31.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in C-Reactive Protein From Baseline to Month 12</title>
        <description>Percent improvement in C-reactive protein from baseline to month 12</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in C-Reactive Protein From Baseline to Month 12</title>
          <description>Percent improvement in C-reactive protein from baseline to month 12</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.57" spread="132.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Improvement in Duration of Morning Stiffness From Baseline to Month 12</title>
        <description>Percent improvement in the duration of morning stiffness from baseline to month 12</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Improvement in Duration of Morning Stiffness From Baseline to Month 12</title>
          <description>Percent improvement in the duration of morning stiffness from baseline to month 12</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and month 12</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.08" spread="156.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death</title>
        <description>Death of the participant on study up to 30 days after the last dose of etanercept</description>
        <time_frame>Up to 8 years</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death of the participant on study up to 30 days after the last dose of etanercept</description>
          <population>All enrolled participants who received at least one dose of etanercept</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Year 2 in Total Sharp Score</title>
        <description>Change from baseline to year 2 in Total Sharp Score. This score has a range of 0 to 398, where 0 = no change and higher scores represent a worsening of joint erosions and joint space narrowing.</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and year 2</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Year 2 in Total Sharp Score</title>
          <description>Change from baseline to year 2 in Total Sharp Score. This score has a range of 0 to 398, where 0 = no change and higher scores represent a worsening of joint erosions and joint space narrowing.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and year 2</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="-10.10" upper_limit="32.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Year 2 in Sharp Score Erosion Subscale</title>
        <description>Change from baseline to year 2 in the joint erosion subscale of the Total Sharp Score. This subscale has a range of 0 to 230, where 0 = no change and higher values represent a worsening in joint erosions.</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and year 2</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Year 2 in Sharp Score Erosion Subscale</title>
          <description>Change from baseline to year 2 in the joint erosion subscale of the Total Sharp Score. This subscale has a range of 0 to 230, where 0 = no change and higher values represent a worsening in joint erosions.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and year 2</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="-8.08" upper_limit="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Year 2 in Sharp Score Joint Space Narrowing Subscale</title>
        <description>Change from baseline to year 2 in the joint space narrowing subscale of the Total Sharp Score. This subscale has a range of 0 to 168, where 0 = no change and higher values represent a worsening of joint space narrowing.</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and year 2</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept (Enbrel)</title>
            <description>Etanercept 50 mg subcutaneous dose weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Year 2 in Sharp Score Joint Space Narrowing Subscale</title>
          <description>Change from baseline to year 2 in the joint space narrowing subscale of the Total Sharp Score. This subscale has a range of 0 to 168, where 0 = no change and higher values represent a worsening of joint space narrowing.</description>
          <population>All enrolled participants who received at least one dose of etanercept and had available data for this outcome measure at baseline and year 2</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="-5.04" upper_limit="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 9.57 years</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Enbrel</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cleft palate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Myxoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pseudomeningocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>B-cell small lymphocytic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Benign colonic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lymphocytic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>T-cell chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Prostatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cystopexy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Incisional hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="320" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

